招生专业
| 院系名称 | 专业大类 | 一级学科 | 专业代码/专业名称 | 学位类型 | 招生类型 |
| 交叉科学研究院 | 医学 | 中药学 | 100800/中药学 | 学术学位 | 博士/硕士 |
| 交叉科学研究院 | 医学 | 中药学 | 105600/中药学 | 专业学位 | 硕士 |
教育经历
1978-1983 浙江医科大学 临床医学专业 获学士学位
1983-1986 上海第二医科大学药理学专业 获硕士学位
1987-1990 上海第二医科大学药理学专业 获博士学位
1993-1995 法国国立健康与卫生研究院（INSERM）博士后
1998-1999 法国里昂第一大学临床药理学 高级访问学者
个人简介与研究方向
现任上海中医药大学首席教授、中药功效成分发掘和利用全国重点实验室常务副主任、上海市中药化学生物学前沿科学基地主任、上海交通大学医学院药物研究所所长等；中国药学会副理事长、上海市药学会理事长、国家高水平中医药重点学科带头人、上海中药学战略创新团队负责人、Transl Neurodegen（IF 12.6）副主编等。历任上海交通大学基础医学院院长、上海交通大学医学院副院长兼研究生院院长、上海中医药大学副校长等。履职全国政协委员，上海市人大常委和浦东新区人大副主任等。
主要从事神经和肿瘤药理学研究，主持国家重点基础研究计划（973）课题、国家“重大新药创制”科技重大专项、科技部国际合作项目和国家自然科学基金等30余项，负责国家NMPA中药科学监管体系建设重点项目。发表Nat Med、Nat Nanotechnol、Cell Metabol、Sci Transl Med、Nat Chem Biol、Adv Sci、J Hepatol、Eur Respir J、Nat Commun、BJP、JMC等高水平SCI论文400余篇，引用＞16000余次，H指数56，列斯坦福大学全球2%顶尖科学家榜单和全球学者学术影响力榜单等。申请或授权国际和国家发明专利50余项。主编《近代中医要集汇刊（80册）》（2023），主编或副主编《药理学》《高等药理学》《临床药理学教程》教材或专著10部。以第一完成人获国家级教学成果二等奖、教育部科技进步一等奖、上海市科技进步一等奖、中华医学科技二等奖等。荣获国务院政府特贴专家、全国优秀教师和上海市优秀学科带头人等。
课题项目
序号 | 课题类型 | 项目时间 | 项目经费 （万元） | 备注 |
1 | “中药功效成分发掘与利用”全国重点实验室 | 2025.01- | 1000 | 常务副主任 |
2 | 中药化学生物学国家中管局高水平重点学科建设项目 | 2023.01-2027.12 | 600 | 主持 |
3 | 上海市三年行动计划 | 2025.01-2027.12 | 1497 | 主持 |
4 | 上海市重大专项 | 2022.01-2026.12 | 1800 | 主持 |
5 | 上海市中药化学生物学前沿研究基地 | 2021.01-2025.12 | 2500 | 主持 |
代表性文章
1. Lin JY#, Wu Y#, Liang XH, Tang M, Sun X, Lu SX, Jin JM, Guo X, Wang B, Chen HZ*, Zhang WD*, Luan X*. A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy. Adv Sci. 2025, e2500311. doi: 10.1002/advs.202500311. Online ahead of print. IF:14.3
2. Shi J#, Song C#*, Zhang P, Wang J, Huang W, Yu T, Wei Z, Wang L, Zhao L, Zhang R, Hou L, Zhang Y, Chen H*, Wang H*. Microglial circDlg1 modulates neuroinflammation by blocking PDE4B ubiquitination-dependent degradation associated with Alzheimer's disease. Theranostics. 2025 Feb 24;15(8):3401-3423. IF: 12.4
3. Ren M#, Sun X#, Lin J, Kan Y, Lu S, Zhang X, Liang R, Wang B, Chen H*, Wu Y*, Luan X*. Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy. J Control Release. 2025, 382:113717. doi: 10.1016/j.jconrel.2025.113717. Online ahead of print. IF:10.5.
4. Gao J#, Song Q#, Gu X, Jiang G, Huang J, Tang Y, Yu R, Wang A, Huang Y, Zheng G*, Chen H*, Gao X*. Intracerebral fate of organic and inorganic nanoparticles is dependent on microglial extracellular vesicle function. Nat Nanotechnol. 2024 Mar;19(3):376-386. IF: 38.1
5. Huang J#, Fu Y#, Wang A, Shi K, Peng Y, Yi Y, Yu R, Gao J, Feng J, Jiang G, Song Q, Jiang J, Chen H*, Gao X*. Brain Delivery of Protein Therapeutics by Cell Matrix-Inspired Biomimetic Nanocarrier. Adv Mater. 2024 Aug;36(31):e2405323. IF: 27.4
6. Lu X#, Jin J#, Wu Y#, Lin J, Zhang X, Lu S, Zhang J, Zhang C, Ren M, Chen H*, Zhang W*, Luan X*. Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy. Bioact Mater. 2024 Sep 25;43:255-272. IF: 18.0
7. Chen Y#, Zhang C#, Huang Y, Ma Y, Song Q, Chen H*, Jiang G*, Gao X*. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev. 2024 Apr;207:115196. IF: 15.2
8. Zhang X#, Wu Y#, Lin J, Lu S, Lu X, Cheng A, Chen H*, Zhang W*, Luan X*. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges. Acta Pharm Sin B. 2024 Sep;14(9):3818-3833. IF: 14.8
9. Wang C#, Zhang M#, Li S, Gong M, Luo MY, Zhang MC, Zou JH, Shen N, Xu L, Lei HM, Bi L, Zhu L, Wang Z, Chen HZ*, Zhou L*, Shen Y*. A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression. Acta Pharm Sin B. 2024 Nov;14(11):4819-4831. IF: 14.8
10. Bian H#, Liang X#, Lu D#, Lin J, Lu X, Jin J, Zhang L, Wu Y*, Chen H*, Zhang W*, Luan X*. In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77-PPARγ Interaction and Its Anti-Breast-Cancer Efficacy. Adv Sci (Weinh). 2024 Jul;11(26):e2308435. IF: 14.3
11. Zhang Y#, Ding X#, Zhang Q, Zeng C, Chen H*, Lu L*. Trichosanthin elicits antitumor activity via MICU3 mediated mitochondria calcium influx. J Adv Res. 2024 Nov 4:S2090-1232(24)00493-4. IF: 11.4
12. Lu J#, Wu K#, Sha X, Lin J, Chen H*, Yu Z*. TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease. Transl Neurodegener. 2024 Oct 29;13(1):52. IF: 10.8
13. Song C#, Huang W, Zhang P, Shi J, Yu T, Wang J, Hu Y, Zhao L, Zhang R, Wang G, Zhang Y, Chen H*, Wang H*. Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification. Transl Neurodegener. 2024 Nov 4;13(1):54. IF: 10.8
14. Tao L#, Yang G#, Sun T#, Jie Tao, Zhu C, Yu H, Cheng Y, Yang Z, Xu M, Jiang Y, Zhang W, Wang Z, Ma W, Wu L, Xue D, Wang D, Yang W, Zhao Y, Horsefield S, Kobe B, Zhang Z, Tang Z, Li Q, Zhai Q, Dooley S, Seki E, Liu P*, Xu J*, Chen H*, Liu C*. Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1. J Hepatol. 2023 Apr;78(4):805-819. IF: 26.8，入选2023年度中医药十大学术进展。
15. Liang Q#, Gong M#, Zou JH, Luo MY, Jiang LL, Wang C, Shen NX, Zhang MC, Xu L, Lei HM, Zhang KR, Zhang R, Zhuang G, Zhu L, Chen HZ*, Zhou L*, Shen Y*. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma. Drug Resist Updat. 2023 May;68:100957. IF: 15.8
16. Wang D#, Gu X#, Ma X, Chen J, Zhang Q, Yu Z, Li J, Hu M, Tan X, Tang Y, Xu J, Xu M, Song Q, Song H, Jiang G, Tang Z, Gao X*, Chen H*. Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming. Acta Pharm Sin B. 2023 Feb;13(2):834-851. IF: 14.8
17. Zhou S#, Huang Y#, Chen Y, Liu Y, Xie L, You Y, Tong S, Xu J, Jiang G, Song Q, Mei N, Ma F, Gao X, Chen H*, Chen J*. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nat Commun. 2023 Jan 26;14(1):435. IF: 14.7
18. Zhang Q#, Song Q#, Yu R, Wang A, Jiang G, Huang Y, Chen J, Xu J, Wang D, Chen H*, Gao X*. Nano-Brake Halts Mitochondrial Dysfunction Cascade to Alleviate Neuropathology and Rescue Alzheimer's Cognitive Deficits. Adv Sci (Weinh). 2023 Mar;10(7):e2204596. IF: 14.3
19. Li JB#, Hu XY#, Chen MW, Xiong CH, Zhao N, Ge YH, Wang H, Gao XL, Xu NJ, Zhao LX, Yu ZH, Chen HZ*, Qiu Y*. p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer's disease. Transl Neurodegener. 2023 Jan 9;12(1):1. IF: 10.8
20. Jiang G#, Wei C#, Chen Y, Lyu Y, Huang J, Chen H*, Gao X*. Targeted drug delivery system inspired by macropinocytosis. J Control Release. 2023 Jul;359:302-314. IF: 10.5
21. Liu Y#, Zhang N#, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H, Xie W, Zhai Q, Li G, Chen H*, Chen X*. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022 Dec;12(12):4365-4377. IF: 14.8
22. Tang Y#, Gao J#, Wang T, Zhang Q, Wang A, Huang M, Yu R, Chen H*, Gao X*. The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles. Acta Pharm Sin B. 2022 Apr;12(4):2043-2056. IF: 14.8
23. Yu Y#, Zhang Z#, Dong X, Yang R, Duan Z, Xiang Z, Li J, Li G, Yan F, Xue H, Jiao D, Lu J, Lu H, Zhang W, Wei Y, Fan S, Li J, Jia J, Zhang J, Ji J, Liu P, Lu H, Zhao H, Chen S, Wei C, Chen H*, Zhu Z*. Pangenomic analysis of Chinese gastric cancer. Nat Commun. 2022 Sep 15;13(1):5412. IF: 14.7
24. Song C#, Zhang Y#, Huang W, Shi J, Huang Q, Jiang M, Qiu Y, Wang T, Chen H*, Wang H*. Circular RNA Cwc27 contributes to Alzheimer's disease pathogenesis by repressing Pur-α activity. Cell Death Differ. 2022 Feb;29(2):393-406. IF: 13.7
25. Mu Y#, Zhang L#, Hu J, Zhou J, Lin HW, He C, Chen HZ*, Zhang L*. A fungal dioxygenase CcTet serves as a eukaryotic 6mA demethylase on duplex DNA. Nat Chem Biol. 2022 Jul;18(7):733-741. IF: 13.0
26. Luo MY#, Zhou Y#, Gu WM, Wang C, Shen NX, Dong JK, Lei HM, Tang YB, Liang Q, Zou JH, Xu L, Ma P, Zhuang G, Bi L, Xu L, Zhu L, Chen HZ*, Shen Y*. Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma. Cancer Res. 2022 Oct 4;82(19):3516-3531. IF: 12.5
27. Lu L#, Zhang H#, Zhou Y, Lin J, Gao W, Yang T, Jin J, Zhang L, Nagle DG, Zhang W, Wu Y*, Chen H*, Luan X*. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Theranostics. 2022 Apr 24;12(7):3456-3473. IF: 12.4
28. Zhang KR#, Zhang YF#, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ*, Zhu L*. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med. 2021 Oct 6;13(614):eabg6428. IF: 15.8
29. Huang R#, Zhang L#, Jin J#, Zhou Y, Zhang H, Lv C, Lu D, Wu Y, Zhang H, Liu S, Chen H*, Luan X*, Zhang W*. Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction. Acta Pharm Sin B. 2021 Nov;11(11):3481-3492. IF: 14.8
30. Liu XL#, Dong X#, Yang SC, Lai X, Liu HJ, Gao Y, Feng HY, Zhu MH, Yuan Y, Lu Q, Lovell JF, Chen HZ*, Fang C*. Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy. Adv Sci (Weinh). 2021 Mar 1;8(8):2003679. IF: 14.3
31. Wang J#, Hu HJ#, Liu ZK, Liu JJ, Wang SS, Cheng Q, Chen HZ*, Song M*. Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer's disease-related pathologies in a senescence-accelerated mouse model. Transl Neurodegener. 2021 Mar 31;10(1):12. IF: 10.8
32. Ni L#, Chen L#, Huang X, Han C, Xu J, Zhang H, Luan X, Zhao Y, Xu J, Yuan W*, Chen H*. Combating COVID-19 with integrated traditional Chinese and Western medicine in China. Acta Pharm Sin B. 2020 Jul;10(7):1149-1162. IF: 14.8
33. Jiang G#, Chen H#, Huang J, Song Q, Chen Y, Gu X, Jiang Z, Huang Y, Lin Y, Feng J, Jiang J, Bao Y, Zheng G, Chen J, Chen H*, Gao X*. Tailored Lipoprotein-Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistance through Receptor-Stimulated Macropinocytosis. Adv Sci (Weinh). 2020 Jan 20;7(5):1903290. IF: 14.3
34. Jin J#, Wu Y#, Chen J, Shen Y, Zhang L, Zhang H, Chen L, Yuan H, Chen H*, Zhang W*, Luan X*. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics. 2020 Aug 8;10(22):10141-10153. IF: 12.4
35. Huang K#, Liang Q#, Zhou Y#, Jiang LL, Gu WM, Luo MY, Tang YB, Wang Y, Lu W, Huang M, Zhang SZ, Zhuang GL, Dai Q, Shen QC, Zhang J, Lei HM, Zhu L, Ye DY, Chen HZ*, Zhou L*, Shen Y*. A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 2019 Dec 3;30(6):1107-1119.e8. IF: 27.7